Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Neoplasms 2Fatigue 2Sleep Wake Disorders 1Recurrence 1Neoplasm Metastasis 1Hematologic Neoplasms 1Depression 1Brain Neoplasms 1Anxiety Disorders 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 64Androgen Antagonists 59Abiraterone Acetate 58apalutamide 56Radiosurgery 52darolutamide 48Radiotherapy 47Leuprolide 47abiraterone 45Docetaxel 42Pluvicto 32Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Radiation 30relugolix 28Surveys and Questionnaires 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24Gonadotropin-Releasing Hormone 23bicalutamide 22Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Methylphenidate × 1 year × Clear all
NCT03772834 2026-05-04

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

NCT01410942 2026-02-20

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
175 enrolled
Genitourinary

Fatigue, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡